資源描述：
《腫瘤分子靶向治療的思考》由會(huì)員上傳分享，免費(fèi)在線(xiàn)閱讀，更多相關(guān)內(nèi)容在教育資源-天天文庫(kù)。
1、BATTLEPROGRAMBiomarker-basedApproachofTargetedTherapyforLungCancerElimination.WaunKiHongetalBiomarkerAnalysisinCoreBiopsy?SelectAdequateTargetTherapy未來(lái)的方向加強(qiáng)癌癥基因分型及藥物基因?qū)W研究，尋找各種靶向治療藥物的適用或預(yù)測(cè)指標(biāo)。Treatingtumorsaccordingtotheirmoleculardefectsandtheirupgradedordowngradedsignaltransductionpa
2、thways.ClinicalPredictorsofGefitiniborErlotinibEfficacyinNSCLCNeversmokerFemalegenderAdenocarcinomaBronchoalveolaradenocarcinomaAsianorigin腫瘤分子靶向治療的思考中山大學(xué)腫瘤防治所管忠震分子靶向治療研究的興起上世紀(jì)70-80年代，癌癥生物學(xué)研究迅速發(fā)展，從分子水平了解腫瘤發(fā)生、發(fā)展的機(jī)制。Scientificresearchhasincreasinglyidentifiedkeygeneticeventscriticaltos
3、peceficcancerdevelopment.TargetingTherapyAnewgenerationofsmallmoleculesorMABsthatrationalydesigndetoinhibitspecificsignaltransductionortranscriptionpathwaysthatarecriticalforcancercellgrowthandsurvival.EGFRBlockadeasCancertherapyTheEGFRautocrinepathwaysplaysanimportantroleinthedevelo
4、pmentandprogressionofhumanepithelialcancer.EGFRactivationtriggersacascadeofsignalsleadingtocellproliferation,productionofantiogenicfactorsandpromotionofinvasionandmetastasis.HighexpressionofEGFRiscommoninawidevarietyofhumancancersandisgenerallyassociatedwithadvanceddiseaseandpoorprog
5、nosis,andwithresistancetohormonetherapy,chemotherapy,orradiotherapy.EGFRBlockadeasCancerTherapy: J.mendelsohn’sHypothesis(Early1980s)TheblockadeofEGFRactivationmayinhibitcancrcellproliferation.CancercellsmaybeselectivelysensitivetoEGFRinhibitionascomparedtonormalcells.Selectiveanti-E
6、GFRagentsmaybedeveloped.靶向治療研究已獲得明顯成果GleevecNorvatisCML,GISTGefitinibAstraZenicaNSCLCErlotinibGenetech,RocheNSCLCErbituxImClone,MerchCRC,H/NHerceptinGenetech,RocheBreastBevacezumabRocheCRC,lungSorafenibBayerRCCSunitinibPfeizerRCC,GIST許多新的分子靶向藥物仍在開(kāi)發(fā)研究中ZD6474(Vandetanib)AZlungGW786034(
7、Pazopanib)GSKRCCCA163048(lxabepilone)BMSBreastEGF10453(Lapatinib)GSKBreastEnzastaurinEil-lillyGBM,NHLDasatinib耐藥CMLPF3512676Pfeizerlung靶向治療藥物取得的成功若干化療無(wú)效（失?。┑牟±〉妹黠@療效Iressa,TarcevaNSCLCPtbasedchemoFailureSorafenib,SunibinibRCC,RefractoryGISTGleevecCML,GISTHerceptinHer2(+)BreastCaErbit
8、uxChemo-resi
